CryoCell International Inc (CCEL) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
CryoCell International Inc stock (CCEL) is currently trading at $3.10. CryoCell International Inc PS ratio (Price-to-Sales) is 0.80. Analyst consensus price target for CCEL is $8.50. WallStSmart rates CCEL as Sell.
- CCEL PE ratio analysis and historical PE chart
- CCEL PS ratio (Price-to-Sales) history and trend
- CCEL intrinsic value — DCF, Graham Number, EPV models
- CCEL stock price prediction 2025 2026 2027 2028 2029 2030
- CCEL fair value vs current price
- CCEL insider transactions and insider buying
- Is CCEL undervalued or overvalued?
- CryoCell International Inc financial analysis — revenue, earnings, cash flow
- CCEL Piotroski F-Score and Altman Z-Score
- CCEL analyst price target and Smart Rating
CryoCell International Inc
📊 No data available
Try selecting a different time range
Smart Analysis
CryoCell International Inc (CCEL) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in peg ratio, return on equity, price/sales. Concerns around market cap and operating margin. Mixed signals suggest waiting for clearer direction before acting.
CryoCell International Inc (CCEL) Key Strengths (3)
Every $100 of shareholder equity generates $129 in profit
Paying less than $1 for every $1 of annual revenue
Good growth relative to its price
Supporting Valuation Data
CryoCell International Inc (CCEL) Areas to Watch (7)
Losing money on operations
Revenue declining -2.30%, a shrinking business
Earnings declining -30.80%, profits shrinking
Company is losing money with a negative profit margin
Very expensive at 9.7x book value
Very low institutional interest at 12.20%
Micro-cap company with very limited liquidity and high volatility
Supporting Valuation Data
CryoCell International Inc (CCEL) Detailed Analysis Report
Overall Assessment
This company scores 37/100 in our Smart Analysis, earning a F grade. Out of 10 metrics analyzed, 3 register as strengths (avg 9.3/10) while 7 fall into concern territory (avg 1.0/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Return on Equity, Price/Sales, PEG Ratio. Valuation metrics including PEG Ratio (1.34), Price/Sales (0.80) suggest the stock is attractively priced. Profitability is solid with Return on Equity at 129.20%.
The Bear Case
The primary concerns are Operating Margin, Revenue Growth, EPS Growth. Some valuation metrics including Price/Book (9.72) suggest expensive pricing. Growth concerns include Revenue Growth at -2.30%, EPS Growth at -30.80%, which may limit upside. Profitability pressure is visible in Operating Margin at -50.60%, Profit Margin at -7.70%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Operating Margin improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 129.20% currently healthy but needing to be sustained. Third, growth sustainability, with Revenue Growth at -2.30% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Operating Margin and Revenue Growth are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
CCEL Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
CCEL's Price-to-Sales ratio of 0.80x trades 50% below its historical average of 1.59x (2th percentile). The current valuation is 76% below its historical high of 3.25x set in Oct 2021, and 8% above its historical low of 0.74x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~1.6x as trailing revenue scaled faster than the stock price.
Compare CCEL with Competitors
Top MEDICAL CARE FACILITIES stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for CryoCell International Inc (CCEL) · HEALTHCARE › MEDICAL CARE FACILITIES
The Big Picture
CryoCell International Inc is in a turnaround phase, with management focused on restoring profitability. Revenue reached 32M with 230% decline year-over-year. The company is currently unprofitable, posting a -7.7% profit margin.
Key Findings
ROE of 12920.0% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
Generating 1M in free cash flow and 1M in operating cash flow. Earnings are translating into actual cash generation.
Revenue contracted 230% YoY. Worth determining whether this is cyclical or structural.
The company is unprofitable with a -7.7% profit margin. The path to breakeven will be the key catalyst.
What to Watch Next
Dividend sustainability with a current yield of 12.5%. Watch payout ratio and free cash flow coverage.
Sector dynamics: monitor MEDICAL CARE FACILITIES industry trends, competitive moves, and regulatory changes that could impact CryoCell International Inc.
Bottom Line
CryoCell International Inc is in turnaround mode. The path to profitability remains the critical question. Speculative investors may see opportunity in the recovery story, but conservative investors should wait for consistent positive earnings before committing capital.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About CryoCell International Inc(CCEL)
NYSE MKT
HEALTHCARE
MEDICAL CARE FACILITIES
USA
Cryo-Cell International, Inc. is dedicated to cell processing and cryogenic cell storage with a focus on collecting and preserving umbilical cord blood stem cells for family use. The company is headquartered in Oldsmar, Florida.